Chromoblastomycosis caused by Rhinocladiella aquaspersa

Medical Mycology

Volumn 42, Issue 3, 2004, Pages 261-265

  Marques, S G ^a   Pedrozo Silva, C M ^a   Resende, Maria Aparecida ^b   Andreata, L S ^b   Costa, M L ^a  

^a FEDERAL UNIVERSITY OF MARANHÃO   (Brazil)

^b FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

Chromoblastomycosis; Forehead lesion; Left face; Rhinocladiella aquaspersa

Indexed keywords

AMPHOTERICIN B; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; KETOCONAZOLE; TERBINAFINE;

ADULT; AGRICULTURAL WORKER; ARTICLE; ASCOMYCETES; BRAZIL; CASE REPORT; CHROMOMYCOSIS; CONIDIUM; DISEASE DURATION; DRUG SENSITIVITY; FUNGUS CULTURE; FUNGUS IDENTIFICATION; HUMAN; HUMAN TISSUE; MALE; NONHUMAN; PHYSICAL EXAMINATION; RHINOCLADIELLA AQUASPERSA; SCLERODERMA; SKIN BIOPSY; SKIN MANIFESTATION;

ARM; ASCOMYCOTA; BIOPSY; BRAZIL; CHROMOBLASTOMYCOSIS; FACE; FOREHEAD; HUMANS; KETOCONAZOLE; LEG; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MITOSPORIC FUNGI;

FUNGI; RHINOCLADIELLA; RHINOCLADIELLA AQUASPERSA;

EID: 3242880230     PISSN: 13693786     EISSN: None     Source Type: Journal    
DOI: 10.1080/13693780310001597700     Document Type: Article

References (25)

1. Rippon JW. Medical Mycology. The subcutaneous mycoses. In: Rippon JW (ed.). The Pathogenic Fungi and the Pathogenic Actinomycetes. Philadelphia: WB Saunders. 1988: 276-296.
2. Kwon-Chung KJ, Bennett JE. Chromoblastomycosis. In: Kwon-Chung KJ, Bennett JE (eds.). Medical Mycology. Philadelphia: Lea & Febiger. 1992: 337-355.
3. Esterre P, Andriantsimahavandy A, Ramarcel ER, Pecarrere JL. Forty years of chromoblastomycosis in Madagascar: a review. Am J Trop Med Hyg 1996; 55: 45-47.
4. Borelli D. Acrotheca aquaspersa nova sp., agente de cromomicosis. Acta Cient Venez 1972; 23: 193-196.
5. Oliveira LG, Resende MA, Lopes CF, Cisalpino EO. Identificação de agentes da cromomicose. An Brasil Dermatol 1977; 52: 1-5.
6. Padhye AA. Identification of etiologic agents of chromoblastomycosis. In: Scientific Publication, No. 479 PHAO: VIth International Conference on the Mycoses, Cartagena, Colombia, 1983. Washington, DC: PHAO, 1986: 87-88.
7. Schell WA, McGinnis MR, Borelli D. Rhinocladiella aquaspersa: a new combination for Acrotheca aquaspersa. Mycotaxon 1983; 17: 341-348.
8. National Committee for Clinical and Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of yeasts. Proposed Standard. Document M-27-P. Villanova, PA: National Committee for Clinical and Laboratory Standards, 1992.
9. Espinel-Ingroff A, Kerkering TM. Spectrophotometric method of inoculum preparation for the in vitro susceptibility testing of filamentous fungi. J Clin Microbiol 1991; 29: 393-394.
10. Espinel-Ingroff A, Dawson K, Pfaller M, et al. Comparative and collaborative evaluation of antifungal susceptibility testing for filamentous fungi. Antimicrob Agents Chemother 1995; 39: 314-319.
11. Gomes MHR, Resende MA. Fonsecaea pedrosoi: lipid composition and determination of susceptibility to amphotericin B. Can J Microbiol 1992; 38: 209-214.
12. Caligiorne RB, Resende MA, Melillo PHC, Peluso CP, Carmo FHS, Azevedo V. In vitro susceptibility of chromoblastomycosis and phaeohyphomycosis agents to antifungal drugs. Med Mycol 1999; 37: 405-409.
13. Bedout C, Gómez BL, Restrepo A. In vitro susceptibility testing of Fonsecaea pedrosoi to antifungals. Rev Inst Med Trop São Paulo 1997; 39: 145-148.
14. Arango M, Jaramillo C, Cortés A, Restrepo A. Auricular chromoblastomycosis caused by Rhinocladiella aquaspersa. Med Mycol 1998; 36: 43-45.
15. Sauerteig E, Hernández R, Salfeder K, Bastidas C. Acute chromoblastomycosis provoked by an insect bite in an immuno-suppressed patient. Mycoses 1998; 41: 191-194.
16. Scholer HJ, Polak A. Resistance to systemic antifungal agents. In: Bryan LE (ed.). Antimicrobial Drug Resistance. Orlando: Academic Press, 1984: 393-460.
17. Vanden Bossche H, Warnock WD, Dupont B, et al. Mechanisms and clinical impact of drug resistance. J Med Vet Mycol 1994; 32(Suppl. 1): 189-202.
18. Vanden Bossche H, Dromer F, Improvisi I, et al. Antifungal drug resistance in pathogenic fungi. Medical Mycology 1998; 38(Suppl. 1): 119-128.
19. Rosenblatt HM, Byrne W, Ament ME, et al. Successful treatment of chronic mucocutaneous candidiasis with ketoconazole. J Pediatrics 1980; 97: 657-660.
20. Horsburgh CR, Kirkpatrick CH. Long-term therapy of chronic mucocutaneous candidiasis with ketoconazole: experience with twenty-one patients. Am J Med 1983; 74(Suppl. 1B): 23-29.
21. Warnock DW, Johnson EM, Richardson MD, et al. Modified response to ketoconazole of Candida albicans from a treatment failure. Lancet 1983; i: 642-643.
22. Smith KJ, Warnock DW, Kennedy CTC, et al. Azole resistance in Candida albicans. J Med Veter Mycol 1986; 24: 133-144.
23. McGinnis MR, Pasarell L. In vitro evaluation of terbinafine and itraconazole against dematiaceous fungi. Med Mycol 1998; 36: 243-246.
24. Esterre P, Inzan CK, Ramarcel ER, et al. Treatment of chromomycosis with terbinafine: preliminary results of an open pilot study. Br J Dermatol 1996; 134: 33-36.
25. Esterre P, Ratsioharana M, Roig P. Potential of terbinafine in the treatment of chromoblastomycosis. Rev Contemp Pharmacother 1997; 8: 357-361.